11,620 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Cibc World Markets Corp

Cibc World Markets Corp purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 11,620 shares of the company’s stock, valued at approximately $951,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC raised its position in Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. increased its holdings in Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after purchasing an additional 485,436 shares during the last quarter. State Street Corp raised its position in Vaxcyte by 1.1% in the third quarter. State Street Corp now owns 3,405,743 shares of the company’s stock valued at $389,174,000 after purchasing an additional 38,596 shares during the period. Franklin Resources Inc. grew its stake in shares of Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after buying an additional 324,560 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Vaxcyte by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after acquiring an additional 259,010 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PCVX. Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte has an average rating of “Buy” and a consensus price target of $147.50.

Insider Activity

In related news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 46,250 shares of company stock valued at $3,840,018. Insiders own 3.10% of the company’s stock.

Vaxcyte Stock Up 0.3 %

Shares of Vaxcyte stock opened at $74.66 on Friday. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The firm’s 50 day moving average is $81.41 and its two-hundred day moving average is $94.10. The firm has a market capitalization of $9.61 billion, a P/E ratio of -16.23 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.